Microcap Ledger FibroBiologics, Inc. $FBLG
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 6,658,193 [10-Q 2026-07-31]
What the company doesAI summary of filing
FibroBiologics is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company has four advanced product candidates in clinical or preclinical stages: CYWC628 for diabetic foot ulcers (Phase 1/2 trial planned for 2026), CYMS101 for multiple sclerosis (IND application planned for 2026), CybroCell for degenerative disc disease (IND clearance received), and CYPS317 for psoriasis (IND application filed December 2025). The company is pre-revenue and generates no sales, instead relying on research and development activities and clinical trials to advance its pipeline toward potential future commercialization. [10-K 2026-02-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$9.12M | −$7.66M | $3.52M | [10-Q 2026-07-31] |
| FY ended Dec 2025 | — | −$18.65M | −$16.39M | $4.89M | [10-K 2026-02-24] |
| FY ended Dec 2024 | — | −$11.16M | −$11.90M | $13.98M | [10-K 2026-02-24] |
- Quarterly cash burn
- −$3.83M
- Cash runway Estimate
- ~2.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 34,659,125 | [10-Q 2024-11-12] |
| 2025-03-28 | 37,735,300 | [10-K 2025-03-31] |
| 2025-05-13 | 38,262,586 | [10-Q 2025-05-14] |
| 2025-07-30 | 41,889,142 | [10-Q 2025-07-31] |
| 2025-10-31 | 51,456,077 | [10-Q 2025-10-31] |
| 2026-02-24 | 67,594,722 | [10-K/A 2026-03-13] |
| 2026-05-01 | 5,208,915 | [10-Q 2026-04-30] |
| 2026-07-31 | 6,658,193 | [10-Q 2026-07-31] |
- Shelf registration
- S-3 filed 2026-07-10; declared effective 2026-07-16 [S-3 2026-07-10]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-24] |
| 2026-02-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-06] |
| 2026-01-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-02] |
| 2025-08-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-08] |
| 2025-07-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Khoja Hamid | grant | 298,508 | $1.68 | [4 2026-09-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-09-18 | 8-K | Shareholder vote results; Regulation FD disclosure |
| 2026-09-17 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-08-24 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-31 | 10-Q | Quarterly report |
| 2026-07-31 | DEF 14A | Proxy statement |
| 2026-07-24 | 8-K | Listing notice or transfer |
| 2026-07-17 | PRE 14A | Proxy statement |
| 2026-07-16 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-10 | S-3 | Registration statement |
Alerts for $FBLG
Email me when FibroBiologics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.